E. Hall

Petra Seibold, Hubert Thierens, Alison M Dunning, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

MRE 11 as a predictive biomarker of outcome following radiotherapy in bladder cancer

R. Huddart, S. Bhattarai, A. Kiltie, 2019 .

Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy.

John Staffurth, Emma Hall, Helen McNair, 2015, International journal of radiation oncology, biology, physics.

CLINICAL STUDIES

D P Dearnaley, R. Eeles, D. Dearnaley, 2022 .

The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004)

R. Huddart, H. Denley, N. James, 2017, British Journal of Cancer.

Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial.

R. Huddart, N. James, E. Hall, 2020, European urology.

Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer.

Emma Hall, Nicholas D James, R. Huddart, 2012, The New England journal of medicine.

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

Emma Hall, Kevin J Harrington, S. Bhide, 2011, The Lancet. Oncology.

Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy.

D. Tait, J. Yarnold, L. Gothard, 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Quality assurance of dysphagia-optimised intensity modulated radiotherapy treatment planning for head and neck cancer

C. Clark, E. Miles, C. Nutting, 2021, Physics and imaging in radiation oncology.

Protocol for hypofractionated adaptive radiotherapy to the bladder within a multicentre phase II randomised trial: radiotherapy planning and delivery guidance

R. Huddart, E. Miles, E. Hall, 2020, BMJ Open.

Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: Results at 4 years

H. Graham, N. Cross, E. Hall, 2005, International journal of cancer.

Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up

R. Eeles, D. Dearnaley, A. Horwich, 2013, British Journal of Cancer.

Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy

K. Hao, H. Ostrer, G. Pandey, 2019, Journal of the National Cancer Institute.

Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer

S. Nill, R. Huddart, U. Oelfke, 2020, Clinical and translational radiation oncology.

Defining bowel dose volume constraints for bladder radiotherapy treatment planning.

R. Huddart, E. Hall, S. Gulliford, 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011)

R. Huddart, E. Hall, C. Moynihan, 2012, Trials.

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Ivanov, Harris, R. Collins, 2005, The Lancet.

Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen

J. Jassem, R. C. Coombes, G. Bertelli, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Aromatase inhibitors as adjuvant therapies in patients with breast cancer

R. Coombes, L. Gibson, E. Hall, 2003, The Journal of Steroid Biochemistry and Molecular Biology.

Current attitudes of head and neck oncologists in the United Kingdom to induction chemotherapy for locally advanced head and neck cancer: a survey of centres participating in a national randomised controlled trial.

S. Bhide, K. Harrington, C. Nutting, 2014, Oral oncology.

Advancing Radiotherapy for Bladder Cancer: Randomised Phase II Trial of Adaptive Image-guided Standard or Dose-escalated Tumour Boost Radiotherapy (RAIDER).

R. Huddart, E. Hall, S. Hafeez, 2021, Clinical oncology (Royal College of Radiologists (Great Britain)).

Hypofractionation for Prostate Cancer: Time to Change.

D. Dearnaley, E. Hall, S. Gulliford, 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

A Randomised Trial of Conventional Care versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases

V. Khoo, N. V. As, K. Franks, 2018, Clinical Oncology.

Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET).

M. V. van Herk, K. Harrington, R. Mackay, 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

Linkage of the CHHiP randomised controlled trial with primary care data: a study investigating ways of supplementing cancer trials and improving evidence-based practice

S. de Lusignan, D. Dearnaley, R. Byford, 2020, BMC Medical Research Methodology.

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)

O. Sartor, S. Oudard, E. Hall, 2018, European urology.

Patient involvement in the design of a phase III trial comparing IMPT and IMRT for oropharyngeal cancer

C. Nutting, C. West, E. Hall, 2021 .

The International Penile Advanced Cancer Trial (InPACT): Rationale and Current Status.

E. Hall, C. Pettaway, N. Watkin, 2019, European urology focus.

Patient Involvement in the Design of a Phase III Trial Comparing Intensity-modulated Proton Therapy and Intensity-modulated Radiotherapy for Oropharyngeal Cancer.

C. Nutting, C. West, E. Hall, 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial

J. Donovan, E. Hall, Robert J. Jones, 2020, Trials.

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

J. Luo, Jun Luo, N. Tunariu, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer

R. Huddart, S. Bhattarai, A. Kiltie, 2019, International journal of radiation oncology, biology, physics.

LIFE AND DEATH OF SPARE (SELECTIVE BLADDER PRESERVATION AGAINST RADICAL EXCISION): REFLECTIONS ON WHY THE SPARE TRIAL CLOSED

R. Huddart, E. Hall, Rebecca Lewis, 2010, BJU international.

Clinical and patient‐reported outcomes of SPARE – a randomised feasibility study of selective bladder preservation versus radical cystectomy

J. Donovan, R. Huddart, D. McLaren, 2017, BJU international.

Fracture Risk in Men with Metastatic Prostate Cancer Treated With Radium-223

C. Parker, A. Padhani, N. Tunariu, 2021, Clinical genitourinary cancer.

Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects

R. Eeles, D. Dearnaley, A. Horwich, 2005, British Journal of Cancer.

Intermediate clinical endpoints in localised prostate cancer.

D. Dearnaley, E. Hall, A. Tree, 2021, The Lancet. Oncology.

Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.

Maarten J. IJzerman, N. Tunariu, L. Terstappen, 2016, European urology focus.

Protocol for tumour-focused dose-escalated adaptive radiotherapy for the radical treatment of bladder cancer in a multicentre phase II randomised controlled trial (RAIDER): radiotherapy planning and delivery guidance

R. Huddart, E. Miles, D. McLaren, 2020, BMJ Open.

Results of the SPARE Feasibility Study – Selective Bladder Preservation Against Radical Excision in Muscle Invasive T2/T3 Transitional Cell Carcinoma of the Bladder (CRUK/07/011)

R. Huddart, E. Hall, Rebecca Lewis, 2012 .

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

S. Cawthorn, R. C. Coombes, E. Hall, 2007, The Lancet. Oncology.

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

S. Pettitt, C. Lord, V. Serra, 2021, Cancer discovery.

R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology

C. Fuller, S. Mook, C. Faivre-Finn, 2017, Front. Oncol..

Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial

D. Dearnaley, V. Khoo, J. Staffurth, 2022, International journal of radiation oncology, biology, physics.

The Efficacy and Safety of Conventional and Hypofractionated High-Dose Radiation Therapy for Prostate Cancer in an Elderly Population: A Subgroup Analysis of the CHHiP Trial.

D. Dearnaley, V. Khoo, C. Parker, 2018, International journal of radiation oncology, biology, physics.

DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer

S. Bhide, K. Harrington, T. Roques, 2016, BMC Cancer.

Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials.

D. Dearnaley, L. Holloway, P. Greer, 2020, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

The MOMENTUM Study: An International Registry for the Evidence-Based Introduction of MR-Guided Adaptive Therapy

B. Erickson, C. Fuller, R. Huddart, 2020, Frontiers in Oncology.

LBA20ANTITUMOUR ACTIVITY OF THE PARP INHIBITOR OLAPARIB IN UNSELECTED SPORADIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC) IN THE TOPARP TRIAL

A. Chinnaiyan, N. Tunariu, J. Bono, 2014 .

Joint models for dynamic prediction in localised prostate cancer: a literature review

E. Hall, N. Porta, Harry Parr, 2022, BMC Medical Research Methodology.

beam therapy The challenges of delivering high quality

R. Mackay, D. Eaton, Ricky A. Sharma, 2019 .

Proton Beam Therapy - the Challenges of Delivering High-quality Evidence of Clinical Benefit.

P. Evans, R. Mackay, D. Eaton, 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial

J. Donovan, T. Powles, J. Catto, 2020, The Lancet.

Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC) – opening of the peri‐operative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) Trial

E. Hall, Rebecca Lewis, A. Birtle, 2012, BJU international.

Results of a randomised phase II study of hypofractionated bladder radiotherapy (RT) with or without image guided adaptive planning (HYBRID - CRUK/12/055).

R. Huddart, V. Khoo, J. Staffurth, 2017 .

Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma

D. Dearnaley, A. Horwich, R. Huddart, 2013, British Journal of Cancer.

The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis☆

R. Huddart, J. Shamash, P. Hutton, 2019, European urology.

Risk of second cancers among a cohort of 2,703 long-term survivors of testicular seminoma treated with radiotherapy.

A. Horwich, E. Hall, J. Bliss, 2010 .

111: A single-arm trial evaluating one cycle of BEP as adjuvant chemotherapy in high-risk, stage 1 non-seminomatous or combined germ cell tumors of the testis (NSGCTT).

R. Huddart, P. Hutton, E. Hall, 2017 .

Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004)

R. Huddart, N. James, E. Hall, 2013, International Journal of Radiation Oncology, Biology, Physics.

Adaptive magnetic resonance image guided radiation for intact localized prostate cancer how to optimally test a rapidly emerging technology

A. Kishan, E. Hall, U. A. van der Heide, 2022, Frontiers in Oncology.

Phase I trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers.

H. Gevensleben, Y. Drew, R. Plummer, 2020, Cancer discovery.

Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations

Y. Drew, R. Plummer, N. Tunariu, 2016 .

Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).

Christopher U. Jones, A. Kishan, M. Sydes, 2022, European urology.

In Regard to Spratt.

D. Dearnaley, B. Gusterson, N. Somaiah, 2018, International journal of radiation oncology, biology, physics.

Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.

C. Ramsay, A. Feber, J. Norrie, 2022, Health technology assessment.

Chemoradiotherapy in Muscle-invasive Bladder Cancer: 10-yr Follow-up of the Phase 3 Randomised Controlled BC2001 Trial.

R. Huddart, E. Hall, Rebecca Lewis, 2022, European urology.

Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III Trials

M. Sydes, D. Dearnaley, L. Holloway, 2020, Frontiers in Oncology.

Successful Patient Acceptance of Randomization Within the Pace Study (Prostate Advances in Comparative Evidence)

I. Kaplan, N. V. As, M. Sanda, 2013 .

Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results

D. Dearnaley, E. Hall, 2017, Translational andrology and urology.

Comparison of hypofractionated high-dose intensity-modulated radiotherapy schedules for prostate cancer: Results from the phase III randomized CHHiP trial (CRUK/06/016).

D. Dearnaley, V. Khoo, J. Logue, 2016 .

How will the CHHiP trial affect the future of prostate radiotherapy?

D. Dearnaley, E. Hall, 2018, Expert review of anticancer therapy.

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.

J. Staffurth, V. Hinder, E. Hall, 2022, The Lancet. Oncology.

Dose-escalated intensity-modulated radiotherapy in patients with locally advanced laryngeal and hypopharyngeal cancers: ART DECO, a phase III randomised controlled trial.

S. Bhide, K. Harrington, T. Roques, 2021, European journal of cancer.

A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer*

P. Lønning, L. Fallowfield, L. Gibson, 2004, The New England journal of medicine.

Safety of exemestane in the Intergroup Exemestane Study.

R. Coombes, E. Hall, J. Bliss, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HERMES: Delivery of a Speedy Prostate Cancer Treatment

E. Hall, R. Westley, A. Tree, 2022, Clinical Oncology.

Inter-Observer Variation in Delineating the Pharyngeal Constrictor Muscle as Organ at Risk in Radiotherapy for Head and Neck Cancer

C. Nutting, D. Mcquaid, E. Hall, 2021, Frontiers in Oncology.

First mature analysis of the Intergroup Exemestane Study.

R. Paridaens, T. Delozier, C. V. D. van de Velde, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patterns of care, tolerability and safety of the first cohort of patients treated on a novel high-field MR-Linac within the MOMENTUM Study: Initial results from a prospective Multi-Institutional Registry.

B. Erickson, C. Fuller, R. Huddart, 2021, International journal of radiation oncology, biology, physics.

Impact of Prostate Cancer Hypofractionation on Patient Reported Outcomes: Baseline to 5 Years Change in the CHHIP Trial

D. Dearnaley, V. Khoo, C. Parker, 2018, International Journal of Radiation Oncology*Biology*Physics.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Annie Gao, Clare Griffin, John Staffurth, 2016, The Lancet. Oncology.

Intermittent androgen suppression for rising PSA level after radiotherapy.

Fred Saad, Emma Hall, Graeme Duncan, 2012, The New England journal of medicine.

Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial

D. Dearnaley, E. Hall, S. Gulliford, 2021, International journal of radiation oncology, biology, physics.

Approaches to the evaluation of rapidly evolving radiotherapy technologies

M. Parmar, C. Faivre-Finn, L. Billingham, 2012 .

Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001)

P. Ellis, D. Cameron, E. Hall, 2014, European journal of cancer.

Recovery of Salivary Function: Contralateral Parotid-sparing Intensity-modulated Radiotherapy versus Bilateral Superficial Lobe Parotid-sparing Intensity-modulated Radiotherapy

S. Bhide, K. Harrington, C. Nutting, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

First results of a phase III multicenter randomized controlled trial of intensity modulated (IMRT) versus conventional radiotherapy (RT) in head and neck cancer (PARSPORT: ISRCTN48243537).

K. Harrington, R. A’Hern, C. Nutting, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

Wei Yuan, Nina Tunariu, Rosalind Eeles, 2015, The New England journal of medicine.

Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients

R. Plummer, N. Tunariu, Juanita Lopez, 2015 .

Genomics of lethal prostate cancer at diagnosis and castration resistance

N. Tunariu, E. Hall, Robert J. Jones, 2019, The Journal of clinical investigation.

Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer

D. Dearnaley, B. Gusterson, N. Somaiah, 2018, International journal of radiation oncology, biology, physics.

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.

A. Chinnaiyan, N. Tunariu, D. Robinson, 2017, Cancer discovery.

Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation

B. Gusterson, N. Somaiah, F. Daley, 2023, EBioMedicine.

Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial

N. Tunariu, D. McLaren, A. Espinasse, 2019, The Lancet. Oncology.

Derivation of dose/volume constraints for the anorectum from clinician and patient-reported outcomes in the CHHiP trial of radiotherapy fractionation.

D. Dearnaley, E. Hall, S. Gulliford, 2020, International journal of radiation oncology, biology, physics.

Evaluation of erectile potency and radiation dose to the penile bulb using image guided radiotherapy in the CHHiP trial

D. Dearnaley, V. Khoo, C. Parker, 2019, Clinical and translational radiation oncology.

Randomized phase III studies of adjuvant chemotherapy with FAMTX or FEMTX in resected gastric cancer. Pooled results of studies from the EORTC GI-group and the ICCG

A. Tres, D. Nitti, M. Lise, 2002 .

Clinical development of new drug–radiotherapy combinations

Richard A. Adams, Kevin J. Harrington, Maria A. Hawkins, 2016, Nature Reviews Clinical Oncology.

BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004).

R. Huddart, C. Cruickshank, E. Hall, 2019, European urology.

Boxing Bladder Cancer with COX-2–specific Inhibition

E. Hall, J. Kelly, 2011, Cancer Prevention Research.

Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC).

J. Donovan, T. Powles, J. Catto, 2018 .

Validation and Reliability Testing of the EORTC QLQ-NMIBC24 Questionnaire Module to Assess Patient-reported Outcomes in Non–Muscle-invasive Bladder Cancer

P. Fayers, N. Aaronson, E. Hall, 2014, European urology.

The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B Study

R. Ratnakumaran, V. Hinder, E. Hall, 2023, Cancers.

OP-JNCI190078 1..12

Sydes, H. Ostrer, G. Pandey, 2019 .

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group.

Mike Clarke, K Wheatley, A Riccardi, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy

E. Hall, D. Sebag‐Montefiore, L. Murray, 2019, Clinical and translational radiation oncology.

TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.

J. Bono, A. Espinasse, E. Hall, 2019, Journal of Clinical Oncology.

Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.

D. Collins, D. Koh, N. Tunariu, 2017, Radiology.

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

G. Rodrigues, J. Staffurth, T. Tsakiridis, 2019, The Lancet. Oncology.

Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

Annie Gao, Clare Griffin, John Staffurth, 2015, The Lancet. Oncology.

Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer.

J. Yarnold, L. Gothard, E. Hall, 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer.

R. Coombes, L. Fallowfield, E. Hall, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis

L. Pickering, N. Vasudev, C. Cruickshank, 2021, British journal of cancer.

Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.

N. Tunariu, Juanita Lopez, U. Banerji, 2020, The Lancet. Oncology.

Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker.

J. Brenton, D. Collins, A. Priest, 2019, Radiology.

Updated outcomes of POUT: A phase III randomized trial of peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC).

T. Powles, J. Catto, E. Hall, 2021 .

Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer

Richard Stock, Matthew R. Sydes, Kyriaki Michailidou, 2016, EBioMedicine.

A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia

R. Peto, F. Mandelli, R. Gray, 1998, British journal of haematology.

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

I. Ellis, M. Dowsett, P. Ellis, 2009, The Lancet.

Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.

I. Ellis, M. Dowsett, P. Ellis, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011)

J. Donovan, R. Huddart, E. Hall, 2011, Trials.

Genomic profiling of primary prostate tumors from patients who develop metastatic castration-resistant prostate cancer (mCRPC).

E. Hall, T. Elliott, M. Varughese, 2018 .

Results of a randomized phase III study of dysphagia-optimized intensity modulated radiotherapy (Do-IMRT) versus standard IMRT (S-IMRT) in head and neck cancer.

S. Bhide, T. Roques, C. Nutting, 2020 .

Failing to Close the Gap Between Evidence and Clinical Practice in Radical Bladder Cancer Radiotherapy.

R. Huddart, C. Griffin, E. Hall, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT Phase III trial.

K. Harrington, C. Clark, M. Partridge, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Re: Marco Roscigno, Maurizio Brausi, Axel Heidenreich, et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. Eur Urol 2011;60:776-83.

E. Hall, Rebecca Lewis, A. Birtle, 2012, European urology.

Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial

R. Huddart, T. Powles, D. Feldman, 2011, Journal of Cancer.

Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity

M. Sydes, R. Eeles, D. Dearnaley, 2016, British Journal of Cancer.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.

Annie Gao, John Staffurth, Peter Kirkbride, 2012, The Lancet. Oncology.

Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial

R. Huddart, N. James, E. Hall, 2019, European urology.

A Road Map for Designing Phase I Clinical Trials of Radiotherapy–Novel Agent Combinations

A. Scarsbrook, E. Hall, M. Forster, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer

D. Dearnaley, C. Parker, C. Cruickshank, 2018, Clinical and translational radiation oncology.

Double-blind randomized phase II study of hyperbaric oxygen in patients with radiation-induced brachial plexopathy.

V. P. Misra, P. Anand, J. Yarnold, 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Non-randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema and tissue fibrosis after radiotherapy for early breast cancer.

J. Yarnold, J. Risdall, L. Gothard, 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)

L. Pickering, C. Cruickshank, E. Hall, 2013, British Journal of Cancer.

Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast induration.

J. Yarnold, A. Pearson, L. Gothard, 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Two-year and lifetime cost-effectiveness of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for head-and-neck cancer.

C. Nutting, E. Hall, S. Wheeler, 2013, International journal of radiation oncology, biology, physics.

Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.

A. Tres, E. Van Cutsem, D. Crivellari, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

PIVOTALboost: A phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK/16/018)

J. Staffurth, A. Henry, C. Cruickshank, 2020, Clinical and translational radiation oncology.

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

N. Tunariu, W. Brugger, D. Talbot, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

2579 Evaluation of clinical decision-making and the use of circulating tumor cells (CTCs) by physicians treating castration-resistant prostate cancer (CRPC)

Maarten J. IJzerman, J. Bono, E. Hall, 2015 .

122: CORE: A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases

V. Khoo, N. V. As, K. Franks, 2017 .

Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials

R. Huddart, R. Mackay, N. James, 2021, The Lancet. Oncology.

Clinical Outcomes of a Randomized Trial of Adaptive Plan-of-the-Day Treatment in Patients Receiving Ultra-hypofractionated Weekly Radiation Therapy for Bladder Cancer

R. Huddart, V. Khoo, J. Staffurth, 2020, International journal of radiation oncology, biology, physics.

Advanced Radiotherapy Technologies Network in the UK (ART-NET) - focus on lung cancer

D. Hawkes, F. V. Heuvel, K. Harrington, 2018 .

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer

A. Feber, P. Cooke, J. McGrath, 2020, BJU international.

Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial

M. Sculpher, P. Saramago, M. Soares, 2019, Clinical genitourinary cancer.

Genitourinary tumors, non-prostate

S. J. Park, I. Tannock, S. Groshen, 2012 .

Clinical management and research priorities for high-risk prostate cancer in the UK: Meeting report of a multidisciplinary panel in conjunction with the NCRI Prostate Cancer Clinical Studies Localised Subgroup

V. Khoo, K. Muir, P. Sooriakumaran, 2016 .

Results of a phase III randomized trial of synchronous chemoradiotherapy (CRT) compared to radiotherapy (RT) alone in muscle-invasive bladder cancer (MIBC) (BC2001 CRUK/01/004).

R. Huddart, N. James, E. Hall, 2010 .

2043 Defining bowel dose constraints for bladder radiotherapy: using data from patients entered into phase III randomised trial

R. Huddart, N. James, E. Hall, 2009 .

BC2001 long-term outcomes: A phase III randomized trial of chemoradiotherapy versus radiotherapy (RT) alone and standard RT versus reduced high-dose volume RT in muscle-invasive bladder cancer.

R. Huddart, N. James, E. Hall, 2017 .

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.

N. Tunariu, U. Banerji, F. Raynaud, 2017 .

Abstract CT322: DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer

A. Chinnaiyan, R. Eeles, N. Tunariu, 2015 .

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT)

I. Ellis, M. Dowsett, P. Ellis, 2009 .

In Reply [to Neven et al] [Letter]

I. Ellis, M. Dowsett, J. Bartlett, 2008 .

Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC).

C. Parker, A. Padhani, D. Koh, 2019, Journal of Clinical Oncology.

Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial.

E. Hall, T. Elliott, P. Flohr, 2017 .

Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer Blazeby,

N. Aaronson, E. Hall, R. Waters, 2014 .

Validation and reliability testing of the EORTC QLQ-NMIBC 24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer

N. Aaronson, E. Hall, R. Waters, 2014 .

Bladder Cancer Validation and Reliability Testing of the EORTC QLQ-NMIBC 24 Questionnaire Module to Assess Patient-reported Outcomes in Non – Muscle-invasive Bladder Cancer

P. Fayers, N. Aaronson, E. Hall, 2014 .

PEARLS – A multicentre phase II/III trial of extended field radiotherapy for androgen sensitive prostate cancer patients with PSMA‐avid pelvic and/or para-aortic lymph nodes at presentation

J. Staffurth, E. Miles, C. Cruickshank, 2022, Clinical and translational radiation oncology.

Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016)

D. Dearnaley, V. Khoo, C. Parker, 2021, European urology oncology.

Impact on quality of life (QoL) of FEC-T compared with FEC or E-CMF: UK Taxotere as Adjuvant Chemotherapy Trial (TACT) 2-year follow-up

D. Cameron, A. Ridolfi, E. Hall, 2008 .

Patients' views of distress & interference with daily activities due to side effects in the TACT (Taxotere as Adjuvant ChemoTherapy) trial

D. Cameron, A. Ridolfi, E. Hall, 2008 .

Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers.

H. Gevensleben, M. Hubank, Juanita Lopez, 2020, Cancer discovery.

Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL)

D. Dearnaley, V. Khoo, J. Staffurth, 2019, International journal of radiation oncology, biology, physics.

Intermittent Androgen Suppression for Rising PSA Level After Radiotherapy

Joseph L. Chin, Celestia S. Higano, Fred Saad, 2013 .

TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer

E. Miles, C. Nutting, J. Langendijk, 2022, Clinical and translational radiation oncology.

BC2001: A multicenter phase III randomized trial of standard versus reduced volume radiotherapy for muscle invasive bladder cancer (ISCRTN:68324339).

R. Huddart, N. James, E. Hall, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised assessment of image guided radiotherapy within a phase 3 trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer

D. Dearnaley, V. Khoo, C. Parker, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Practice-changing radiation therapy trials for the treatment of cancer: where are we 150 years after the birth of Marie Curie?

R. Huddart, C. Faivre-Finn, C. Coles, 2018, British Journal of Cancer.

Forward- and Inverse-Planned Intensity-Modulated Radiotherapy in the CHHiP Trial: A Comparison of Dosimetry and Normal Tissue Toxicity

D. Dearnaley, V. Khoo, S. Hassan, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

Results from the biomarker-driven basket trial of RO5126766 (CH5127566), a potent RAF/MEK inhibitor, in RAS- or RAF-mutated malignancies including multiple myeloma.

N. Tunariu, Juanita Lopez, U. Banerji, 2017 .

Reduced dose posterior to prostate correlates with increased PSA progression in voxel-based analysis of 3 randomised phase 3 trials.

M. Sydes, D. Dearnaley, L. Holloway, 2020, International journal of radiation oncology, biology, physics.

Hypo-Fractionation in Muscle-Invasive Bladder Cancer: An Individual Patient Data (IPD) Meta-Analysis of the BC2001 and BCON Trials

R. Huddart, N. James, P. Hoskin, 2019, International Journal of Radiation Oncology*Biology*Physics.

Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK/08/004)

S. Bhide, K. Harrington, C. Nutting, 2018, European journal of cancer.

Results of a 2 x 2 Phase III Randomized Trial of Synchronous Chemo-radiotherapy (CRT) Compared to Radiotherapy (RT) Alone and Standard vs. Reduced High Volume RT in Muscle Invasive Bladder Cancer (MIBC) (BC2001 CRUK/01/004)

R. Huddart, N. James, E. Hall, 2010 .

Impact on quality of life (QL) during chemotherapy (CT) of FEC-T compared to FEC or E-CMF: Results from the UK NCRI Taxotere as Adjuvant Chemotherapy Trial (TACT)

D. Cameron, E. Hall, J. Bliss, 2005 .

PACE-A: An international phase 3 randomised controlled trial (RCT) comparing stereotactic body radiotherapy (SBRT) to surgery for localised prostate cancer (LPCa)—Primary endpoint analysis.

A. Thompson, C. Griffin, E. Hall, 2023, Journal of Clinical Oncology.

A Phase I Trial of CT900, a Novel α-Folate Receptor–Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer

N. Tunariu, Juanita Lopez, U. Banerji, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.

S. Bhide, T. Roques, C. Nutting, 2023, The Lancet. Oncology.

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.

S. Bhide, K. Harrington, C. Clark, 2011, The Lancet. Oncology.

Radiotherapy Quality Assurance for the CHHiP Trial: Conventional Versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy in Prostate Cancer.

D. Dearnaley, V. Khoo, C. Clark, 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

Radiotherapy Trial Set-up in the UK: Identifying Inefficiencies and Potential Solutions.

C. Coles, E. Miles, E. Hall, 2020, Clinical oncology (Royal College of Radiologists (Great Britain)).

PACE: Analysis of acute toxicity in PACE-B, an international phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) to conventionally fractionated or moderately hypofractionated external beam radiotherapy (CFMHRT) for localized prostate cancer (LPCa).

J. Staffurth, V. Hinder, C. Griffin, 2019, Journal of Clinical Oncology.

Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

P. Lønning, J. Forbes, R. Coombes, 2007, The Lancet.

8LBA 5 year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): report from the CHHiP Trial Investigators Group

D. Dearnaley, V. Khoo, J. Logue, 2015 .

A Randomized Trial Of Exemestane After Two To Three Years Of Tamoxifen Therapy In Postmenopausal Women With Primary Breast Cancer.

P. Lønning, L. Fallowfield, L. Gibson, 2004 .

Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial

S. Bhide, K. Harrington, C. Clark, 2011, The Lancet. Oncology.

The Radiotherapy Clinical Trial Research Landscape in the UK Between 2004 and 2013: A Cross-sectional Analysis.

R. Huddart, C. Coles, C. Nutting, 2015, Clinical oncology (Royal College of Radiologists (Great Britain)).

Methodological considerations in the evaluation of radiotherapy technologies.

R. Mackay, L. Billingham, J. Staffurth, 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

Intermittent androgen suppression for rising PSA level after radiotherapy.

F. Saad, J. Chin, G. Duncan, 2012, The New England journal of medicine.

Gastrointestinal Toxicity Prediction Not Influenced By Rectal Contour or Dose-Volume Histogram Definition: Toxicity Prediction with Different Rectal Definitions.

D. Dearnaley, E. Hall, S. Gulliford, 2023, International journal of radiation oncology, biology, physics.

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial

D. Dearnaley, V. Khoo, C. Parker, 2016, The Lancet. Oncology.

Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy

E. Hall, D. Sebag‐Montefiore, L. Murray, 2019, Clinical and translational radiation oncology.

Intermittent androgen suppression for rising PSA level after radiotherapy.

F. Saad, J. Chin, G. Duncan, 2012, The New England journal of medicine.

Title : A randomised assessment of image guided radiotherapy within a phase 3 trial of Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer ( CHHiP )

Parker, D. Dearnaley, V. Khoo, 2018 .

Randomized Noninferiority Trial of Reduced High-Dose Volume Versus Standard Volume Radiation Therapy for Muscle-Invasive Bladder Cancer: Results of the BC2001 Trial (CRUK/01/004)

R. Huddart, N. James, E. Hall, 2013, International journal of radiation oncology, biology, physics.